Journal of Clinical and Aesthetic Dermatology

Updates on Psoriasis & Cutaneou Oncology

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link: http://jcadonline.epubxp.com/i/882293

Contents of this Issue

Navigation

Page 38 of 43

S39 P r o c e e D i n G s JCAD jOUrnAl Of ClInICAl And AEsthEtIC dErMAtOlOgy september 2017 • volume 10 • number 9 • supplement subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol. 2007;178(4):2229–2240. 91. nograles Ke, Zaba lc, Guttman-yassky e, et al. th17 cytokines interleukin (il)-17 and il-22 modulate distinct ingammatory and keratinocyte-response pathways. the British journal of dermatology. 2008;159(5):1092–1102. 92. nestle fo, Kaplan DH, Barker J. Psoriasis. New Engl J Med. 2009;361(5):496–509. 93. Kaudman c, aria n, toichi e, et al. a phase 1 study evaluating the safety, pharmacokinetics, and clinical response of a human il-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123:1037– 1044. 94. leonardi cl, Kimball aB, Papp Ka, et al. eecacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76- week results from a randomised, double-blind, placebo-controlled trial (PHoenix 1). Lancet. 2008;371(9625):1665–1674. 95. Papp Ka, langley rG, lebwohl M, et al. eecacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52- week results from a randomised, double-blind, placebo-controlled trial (PHoenix 2). Lancet. 2008;371(9625):1675–1684. 96. Harden J, Johnson-Huang l, chamian M, et al. Humanized anti-ifn-gamma (HuZaf) in the treatment of psoriasis. J Allergy Clin Immunol. 2015;135(2):553–6. 97. amatya n, Garg av, Gaden sl. il-17 signaling: the yin and the yang. Trends Immunol. 2017;38(5):310–322. 98. Gaden sl. structure and signaling in the il-17 receptor family. Nat Rev Immunol. 2009;9(8):556–567. 99. Hueber W, Patel DD, Dryja t, et al. edects of ain457, a fully human antibody to interleukin-17a, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72. 100. Papp Ka, reid c, foley P, et al. anti-il-17 receptor antibody aMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase i, randomized, placebo-controlled trial. J Invest Dermatol. 2012;132(10):2466–2469. 101. russell cB, rand H, Bigler J, et al. Gene expression profles normalized in psoriatic skin by treatment with brodalumab, a human anti-il-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828–3836. 102. leonardi c, Matheson r, Zachariae c, et al. anti- interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190–1199. 103. Puig l. the role of il 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–534. 104. nawas Z, Hatch M, ramos e, et al. a review of guselkumab, an il-23 inhibitor, for moderate-to-severe plaque psoriasis. Skin Therapy Lett. 2017;22(2):8–10. 105. reich K, armstrong aW, foley P, et al. eecacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase iii, double-blind, placebo- and active comparator-controlled voyaGe 2 trial. J Am Acad Dermatol. 2017;76(3):418–431. 106. reichert JM. antibodies to watch in 2017. Mabs. 2017;9(2):167–181. 107. Papp Ka, Blauvelt a, Bukhalo M, et al. risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med. 2017;376(16):1551–1560. 108. Kim J, Krueger JG. Highly edective new treatments for psoriasis target the il-23/type 17 t cell autoimmune axis. Annu Rev Med. 2017;68:255–269. 109. Kim J, oh cH, Jeon J, et al. Molecular phenotyping small (asian) versus large (Western) plaque psoriasis shows common activation of il-17 pathway genes but diderent regulatory gene sets. J Invest Dermatol. 2016;136(1):161–172. 110. Gelfand JM, stern rs, nijsten t, et al. the prevalence of psoriasis in african americans: results from a population- based study. J Am Acad Dermatol. 2005;52(1):23-26. 111. lande r, Botti e, Jandus c, et al. the antimicrobial peptide ll37 is a t-cell autoantigen in psoriasis. Nat Commun. 2014;5:5621. 112. Ganguly D, chamilos G, lande r, et al. self-rna- antimicrobial peptide complexes activate human dendritic cells through tlr7 and tlr8. J Exp Med. 2009;206(9):1983–1994. 113. lande r, Gregorio J, facchinetti v, et al. Plasmacytoid dendritic cells sense self-Dna coupled with antimicrobial peptide. Nature. 2007;449(7162):564–569. 114. chamilos G, Gregorio J, Meller s, et al. cytosolic sensing of extracellular self-Dna transported into monocytes by the antimicrobial peptide ll37. Blood. 2012;120(18):3699–3707. 115. nair rP, stuart Pe, nistor i, et al. sequence and haplotype analysis supports Hla-c as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827–851. 116. arakawa a, siewert K, stohr J, et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med. 2015;212(13):2203–2212. 117. clark ra. skin resident t cells: the ups and downs of on site immunity. J Invest Dermatol. 2010 feb; 130(2): 362– 370. 118. Gulati n, suarez-farinas M, correa da rosa J, Krueger JG. Psoriasis is characterized by defcient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149. 119. american cancer society. skin cancer. 2017; https://www.cancer.org/cancer/skin-cancer.html. accessed 21 apr 2017. 120. nindl i, Gottschling M, stockgeth e. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers. 2007;23(4):247–259. 121. Zentrum fur Krebsregisterdaten. epidemiologische Krebsregistrierung in Deutschland. Krebs in Deutschland. 2008;.http://www.krebsdaten.de/Krebs/De/content/Pu blikationen/Krebs_in_Deutschland/kid_2015/kid_2015 _epi_registrierung.pdf;jsessionid=6414e9aeee7e73714 e806e983D4fDe5B.1_cid381?__blob=publicationfile. accessed 21 apr 2017. 122. Doorbar J. the papillomavirus life cycle. J Clin Virol. 2005;32:7–15 123. stockgeth e. the importance of treating the feld in actinic keratosis. J Eur Acad Dermatol Venereol. 2017;31 suppl 2:8–11 124. Padilla rs, sebastian s, Jiang Z, nindl i, larson r. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol. 2010;146(3):288– 293. 125. fernandez-figueras Mt, carrato c, saenz x, et al. actinic keratosis with atypical basal cells (aK i) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol. 2015;29(5):991–997. 126. stockgeth e, Hinrichs B, surber c, christophers e. Prevention initiative for dermatological malignancies: where do we stand? Br J Dermatol. 2012;167 suppl 2:v– vi. 127. stockgeth e. updates on the biology and treatment of actinic keratosis. Presented at the 13th congress of the eaDo; 2017 May 3–6. 128. Meyer t, surber c, french le, stockgeth e. resiquimod, a topical drug for viral skin lesions and skin cancer. Expert Opin Investig Drugs. 2013;22(1):149–159. 129. Hengge ur, ruzicka t. topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg. 2004;30(8):1101–1112. 130. szeimies rM, Bichel J, ortonne JP, stockgeth e, lee J, Meng tc. a phase ii dose-ranging study of topical resiquimod to treat actinic keratosis. Br J Dermatol. 2008;159(1):205–210. 131. lebwohl M, shumack s, stein Gold l, Melgaard a, larsson t, tyring sK. long-term follow-up study of ingenol mebutate gel for the treatment of actinic keratoses. JAMA Dermatol. 2013;149(6):666–670. 132. lebwohl M, swanson n, anderson ll, Melgaard a, xu Z, Berman B. ingenol mebutate gel for actinic keratosis. N Engl J Med. 2012;366(11):1010–1019. 133. ogbourne sM, suhrbier a, Jones B, et al. antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res. 2004;64(8):2833–2839. 134. challacombe JM, suhrbier a, Parsons PG, et al. neutrophils are a key component of the antitumor eecacy of topical chemotherapy with ingenol-3- angelate. J Immunol. 2006;177(11):8123–8132. 135. ersvaer e, Kittang ao, Hampson P, et al. the protein kinase c agonist PeP005 (ingenol 3-angelate) in the treatment of human cancer: a balance between eecacy and toxicity. Toxins (Basel). 2010;2(1):174–194. 136. Berman B, amini s, valins W, Block s. Pharmacotherapy of actinic keratosis. Expert Opin Pharmacother. 2009;10(18):3015–3031. 137. Hampson P, Kavanagh D, smith e, Wang K, lord JM, ed rainger G. the anti-tumor agent, ingenol-3-angelate (PeP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKc-delta dependent manner. Cancer Immunol

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Updates on Psoriasis & Cutaneou Oncology